Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296067450> ?p ?o ?g. }
- W4296067450 endingPage "10" @default.
- W4296067450 startingPage "1" @default.
- W4296067450 abstract "OBJECTIVE Immune checkpoint inhibitors (ICIs) and stereotactic radiosurgery (SRS) are commonly utilized in the management of brain metastases. Treatment-related imaging changes (TRICs) are a frequently observed clinical manifestation and are commonly classified as imaging-defined radiation necrosis. However, these findings are not well characterized and may predict a response to SRS and ICIs. The objective of this study was to investigate predictors of TRICs and their impact on patient survival. METHODS This retrospective multicenter cohort study was conducted through the International Radiosurgery Research Foundation. Member institutions submitted de-identified clinical and dosimetric data for patients with non–small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) brain metastases that had been treated with SRS and ICIs. Data were collected from March 2020 to February 2021. Univariable and multivariable Cox and logistic regression analyses were performed. The Kaplan-Meier method was used to evaluate overall survival (OS). The diagnosis-specific graded prognostic assessment was used to guide variable selection. TRICs were determined on the basis of MRI, PET/CT, or MR spectroscopy, and consensus by local clinical providers was required. RESULTS The analysis included 697 patients with 4536 brain metastases across 11 international institutions in 4 countries. The median follow-up after SRS was 13.6 months. The median age was 66 years (IQR 58–73 years), 54.1% of patients were male, and 57.3%, 36.3%, and 6.4% of tumors were NSCLC, melanoma, and RCC, respectively. All patients had undergone single-fraction radiosurgery to a median margin dose of 20 Gy (IQR 18–20 Gy). TRICs were observed in 9.8% of patients. The median OS for all patients was 24.5 months. On univariable analysis, Karnofsky Performance Status (KPS; HR 0.98, p < 0.001), TRICs (HR 0.67, p = 0.03), female sex (HR 0.67, p < 0.001), and prior resection (HR 0.60, p = 0.03) were associated with improved OS. On multivariable analysis, KPS (HR 0.98, p < 0.001) and TRICs (HR 0.66, p = 0.03) were associated with improved OS. A brain volume receiving ≥ 12 Gy of radiation (V12Gy) ≥ 10 cm 3 (OR 2.78, p < 0.001), prior whole-brain radiation therapy (OR 3.46, p = 0.006), and RCC histology (OR 3.10, p = 0.01) were associated with an increased probability of developing TRICs. The median OS rates in patients with and without TRICs were 29.0 and 23.1 months, respectively (p = 0.03, log-rank test). CONCLUSIONS TRICs following ICI and SRS were associated with a median OS benefit of approximately 6 months in this retrospective multicenter study. Further prospective study and additional stratification are needed to validate these findings and further elucidate the role and etiology of this common clinical scenario." @default.
- W4296067450 created "2022-09-17" @default.
- W4296067450 creator A5006288322 @default.
- W4296067450 creator A5008470421 @default.
- W4296067450 creator A5011427447 @default.
- W4296067450 creator A5013552789 @default.
- W4296067450 creator A5015291806 @default.
- W4296067450 creator A5020032572 @default.
- W4296067450 creator A5025518996 @default.
- W4296067450 creator A5026165731 @default.
- W4296067450 creator A5030315115 @default.
- W4296067450 creator A5035416012 @default.
- W4296067450 creator A5036139080 @default.
- W4296067450 creator A5037247530 @default.
- W4296067450 creator A5038365251 @default.
- W4296067450 creator A5043879863 @default.
- W4296067450 creator A5045332116 @default.
- W4296067450 creator A5046359356 @default.
- W4296067450 creator A5047179225 @default.
- W4296067450 creator A5047693308 @default.
- W4296067450 creator A5059099861 @default.
- W4296067450 creator A5059128200 @default.
- W4296067450 creator A5059695558 @default.
- W4296067450 creator A5060123959 @default.
- W4296067450 creator A5065446151 @default.
- W4296067450 creator A5067709692 @default.
- W4296067450 creator A5069715843 @default.
- W4296067450 creator A5074152912 @default.
- W4296067450 creator A5078402900 @default.
- W4296067450 creator A5085224345 @default.
- W4296067450 creator A5085362780 @default.
- W4296067450 creator A5088673454 @default.
- W4296067450 creator A5090748784 @default.
- W4296067450 creator A5091828411 @default.
- W4296067450 date "2022-09-01" @default.
- W4296067450 modified "2023-10-18" @default.
- W4296067450 title "Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved outcomes in patients with brain metastases: an international multicenter study of 697 patients" @default.
- W4296067450 cites W1537483891 @default.
- W4296067450 cites W1968221752 @default.
- W4296067450 cites W1999020268 @default.
- W4296067450 cites W2003917401 @default.
- W4296067450 cites W2017660654 @default.
- W4296067450 cites W2052828107 @default.
- W4296067450 cites W2074933858 @default.
- W4296067450 cites W2075496679 @default.
- W4296067450 cites W2111406583 @default.
- W4296067450 cites W2155073814 @default.
- W4296067450 cites W2159314579 @default.
- W4296067450 cites W2170744163 @default.
- W4296067450 cites W2197694832 @default.
- W4296067450 cites W2329793926 @default.
- W4296067450 cites W2415633845 @default.
- W4296067450 cites W2492450141 @default.
- W4296067450 cites W2569790571 @default.
- W4296067450 cites W2726463501 @default.
- W4296067450 cites W2770305510 @default.
- W4296067450 cites W2782652081 @default.
- W4296067450 cites W2793214654 @default.
- W4296067450 cites W2806930103 @default.
- W4296067450 cites W2884199837 @default.
- W4296067450 cites W2888298425 @default.
- W4296067450 cites W2890381929 @default.
- W4296067450 cites W2893363212 @default.
- W4296067450 cites W2899172402 @default.
- W4296067450 cites W2917864325 @default.
- W4296067450 cites W2950990372 @default.
- W4296067450 cites W2969978317 @default.
- W4296067450 cites W3005704292 @default.
- W4296067450 cites W3006443866 @default.
- W4296067450 cites W3007081145 @default.
- W4296067450 cites W3040456262 @default.
- W4296067450 cites W3044423036 @default.
- W4296067450 cites W3086164260 @default.
- W4296067450 cites W3172328329 @default.
- W4296067450 cites W3202057530 @default.
- W4296067450 cites W4207010522 @default.
- W4296067450 cites W4280570800 @default.
- W4296067450 doi "https://doi.org/10.3171/2022.7.jns22752" @default.
- W4296067450 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36115055" @default.
- W4296067450 hasPublicationYear "2022" @default.
- W4296067450 type Work @default.
- W4296067450 citedByCount "9" @default.
- W4296067450 countsByYear W42960674502022 @default.
- W4296067450 countsByYear W42960674502023 @default.
- W4296067450 crossrefType "journal-article" @default.
- W4296067450 hasAuthorship W4296067450A5006288322 @default.
- W4296067450 hasAuthorship W4296067450A5008470421 @default.
- W4296067450 hasAuthorship W4296067450A5011427447 @default.
- W4296067450 hasAuthorship W4296067450A5013552789 @default.
- W4296067450 hasAuthorship W4296067450A5015291806 @default.
- W4296067450 hasAuthorship W4296067450A5020032572 @default.
- W4296067450 hasAuthorship W4296067450A5025518996 @default.
- W4296067450 hasAuthorship W4296067450A5026165731 @default.
- W4296067450 hasAuthorship W4296067450A5030315115 @default.
- W4296067450 hasAuthorship W4296067450A5035416012 @default.
- W4296067450 hasAuthorship W4296067450A5036139080 @default.
- W4296067450 hasAuthorship W4296067450A5037247530 @default.
- W4296067450 hasAuthorship W4296067450A5038365251 @default.